New treatment of hepatitis C (Direct Acting Antiviral)
author
Abstract:
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for the patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention, recently in Iran new drug direct Acting agent (DAA) was developed that may be equivalent to original drugs that will hope to treat HCV and eliminated HCV in future
similar resources
Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment.
PURPOSE OF REVIEW Approximately 150-175 million people are infected with hepatitis C virus (HCV). Until very recently, the complexity, cost and poor efficacy and tolerability of pegylated interferon and ribavirin (PEG-RBV) treatment have hindered scale up in low-income and middle-income countries (L&MICs). Similarly, the diagnostic and monitoring algorithm associated with PEG-RBV has been expen...
full textDirect-acting antiviral agents in patients with hepatitis C cirrhosis.
Patients with cirrhosis who are infected with hepatitis C virus (HCV) are the most in need of antiviral treatment. Virologic cure improves fibrosis and quality of life while reducing liver-related morbidity and mortality. In mid-2011, the addition of direct-acting antiviral agents (DAAs)-the protease inhibitors boceprevir (Victrelis, Merck) and telaprevir (Incivek, Vertex)-to pegylated interfer...
full textDirect-acting antiviral medications for chronic hepatitis C virus infection.
Treatment of hepatitis C virus has traditionally been difficult because of low rates of treatment success and high rates of treatment discontinuation due to side effects. Current standard therapy consists of pegylated interferon α and ribavirin, both of which have nonspecific and largely unknown mechanisms of action. New therapies are in development that act directly on the hepatitis C virus at...
full textNew strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents
Persistent hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma and the major indication for liver transplantation in adults. Current standard of care treatment (SOC) with pegylated-interferon-α 2 and ribavirin (RBV) has a limited efficacy and is associated with significant side effects frequently associated with poor compliance or t...
full textCauses of treatment failure for hepatitis C in the era of direct-acting antiviral therapy.
Hepatitis C therapy in the era of the newer direct-acting antiviral agents has radically changed our treatment schemes by achieving very high rates of sustained virological response. However, treatment with direct antiviral agents fails in a subgroup of patients. This group of so-called difficult-to-treat individuals is the subject of this paper, which reviews the causes of virological failure,...
full textDirect-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
Hepatitis C virus (HCV) is a leading cause of cirrhosis and hepatocellular carcinoma (HCC) in the US and Japan. Therefore, eradication of HCV may reduce the occurrence of HCC in HCV-infected individuals. In 2011, the use of first-generation HCV NS3/4A protease inhibitors such as telaprevir and boceprevir was initiated for clinical treatment of HCV. Administration of telaprevir and boceprevir pl...
full textMy Resources
Journal title
volume 27 issue 5
pages 1505- 1515
publication date 2019-10
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023